Gene Therapy, Pharma

Top 20 players: Everybody loves an orphan — especially when they come with blockbuster sales and a long run of exclusivity

Rare diseases are a big business in the biopharma world. And they’re getting bigger every year.

Advantaged by regulatory groups in the US and the world over, attracted by lower research costs with smaller studies and the prospect of fielding a blockbuster with a small group of reps, biopharma has responded with a burst of new therapies. And now that the gene therapy era is upon us, we’re seeing the big players step up to buy a significant position for themselves in this booming market.

Evaluate’s Karen Pomeranz just wrapped up a deep dive on the topic, and concluded that we’ll continue to see dramatic growth in the field of orphan drugs as these trends continue to play out with a growing pot for the top players to draw from.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->